Trending News

Cancer research in laboratory
#AstraZeneca #Breast cancer #Cancer research #National Institute for Health and Care Excellence (NICE) #Oncology #Prostate cancer #The Institute of Cancer Research #UK

NICE approves olaparib for early-stage breast cancer and prostate cancer

The UK’s National Institute for Health and Clinical Excellence (NICE) has recommended that Lynparza (olaparib) can be used for NHS patients with both early-stage breast cancer and prostate cancer. Olaparib is PARP inhibitor that targets cancers linked to faulty BRCA1 or BRCA2 genes and works across many different cancer types. The… Read More

#News #Regulatory #Trending News

Hospital patient on ventilator
#Covid-19 #Covid-19 treatment #FDA #InflaRx #Monoclonal antibodies

FDA okays Gohibic for emergency use in Covid-19 patients

Gohibic (vilobelimab) has been granted an Emergency Use Authorization (EUA) by the US Food and Drug Administration (FDA) for the treatment of Covid-19 in hospitalised adults. The monoclonal anti-human complement factor C5a antibody should be initiated within 48 hours of receiving invasive mechanical ventilation (IMV) or… Read More

#News #Trending News

Idiopathic intracranial hypertension
#Brain #Neuroinflammation #Neurology #Phase II trial #Type 2 diabetes #University of Birmingham

Type 2 diabetes drug could treat blinding IIH headaches

Patients with ‘blinding’ headaches known as idiopathic intracranial hypertension (IIH) could be treated with an injectable peptide used for type 2 diabetes, a new trial has found. The study was led by a team of neurologists from the University of Birmingham and University Hospitals Birmingham, and… Read More

#News #Trending News

Osteoarthritis
#Age-related diseases (ARDs) #Ageing #AKL Therapeutics #Arthritis

Osteoarthritis drug could delay the ageing process

New data suggest that AKL Therapeutics’ investigational oral osteoarthritis (OA) drug APPA may have a dual effect on age-related cellular senescence. Senescence, a process in which cells stop dividing, plays a major role in the development of many age-related diseases, including OA. The study,… Read More

#News #Trending News

T cell attacking Covid-19
#Covid-19 #Covid-19 vaccine #Immune response #Immunology / Virology & Vaccines #SARS-CoV-2 #T cell activation

Covid-19 causes long-term damage to the immune system

New findings suggest that the SARS-CoV-2 virus damages an important immune-cell response. The quality of CD8+ T cell response to two doses of the Pfizer-BioNTech Covid-19 vaccine was considerably lower in people with prior SARS-CoV-2 infection compared to people without prior infection, the US study found. Read More

#News #Trending News

CAR-T therapy
#Cancer research #CAR-T #Cell therapy #CRISPR #CRISPR-Cas9 #Gene editing #Oncology #Solid tumours

Double knockout strategy could boost CAR-T in solid tumours

A new approach that delivers a ‘one-two punch’ to help T cells attack solid tumours is the focus of a preclinical study by researchers from the Perelman School of Medicine at the University of Pennsylvania. The findings showed that targeting two regulators that control gene functions… Read More

#Cancer Research #News #Trending News

Cancer cell
#Breast cancer #Breast Cancer Now #Cancer research #Institute of Cancer Research #Oncology

New discovery could help prevent secondary breast cancer

Scientists have discovered why breast cancer cells that have spread to the lungs may ‘wake up’ following years of sleep – forming incurable secondary tumours. Patients with oestrogen receptor positive (ER+) breast cancer – the most common type – have a continued risk of their cancer… Read More

#Cancer Research #News #Trending News

Dr Edo Kon
#Antibiotic resistance #Antimicrobial resistance (AMR) #Bacteria #Immunology / Virology & Vaccines #mRNA #mRNA-based vaccines

mRNA vaccine 100% effective against deadly bacteria

For the first time, researchers have developed an mRNA vaccine that is 100% effective against a type of bacteria that is lethal to humans, paving the way for effective vaccination against antibiotic-resistant bacteria. The study, conducted in an animal model, demonstrated that all treated animals were… Read More

#News #Trending News

#Clinical trial #CRISPR #FDA #Gene editing #Gene therapy #In vivo #Intellia Therapeutics

FDA clears in vivo gene editing therapy for trials in US

The US Food and Drug Administration (FDA) has cleared Intellia Therapeutics’ Investigational New Drug (IND) application for NTLA-2002 for the treatment of hereditary angioedema (HAE).  Intellia is a clinical-stage genome editing company focused on developing potentially curative therapies using CRISPR-based technologies.   The decision will enable the company to include the… Read More

#News #Regulatory #Trending News

CAR-T cell attacking cancer
#Cancer immunotherapy #Cancer research #CAR-T #Cell therapy #Immunotherapy #Karolinska Institutet #Oncology

CAR-T cell therapy holds promise for ovarian cancer

CAR-T cell therapy is effective in mice with ovarian cancer, according to a study published in The Journal for ImmunoTherapy of Cancer.   The study authors, who work at Karolinska Institutet, hope that the discovery will pave the way for a clinical trial… Read More

#Cancer Research #News #Trending News

The Backstop solution for the Irish border
#Association of the British Pharmaceutical Industry #European Commission #Northern Ireland #Pharmaceutical industry #UK government

Windsor Framework addresses drug supply issues in NI

The European Commission and the UK Government have reached a political agreement that they hope will address the challenges faced by citizens and businesses in Northern Ireland (NI) following Brexit. The Windsor Framework, which focuses on a variety of issues, including supply of medicines, constitutes a comprehensive set of joint… Read More

#News #Trending News

Rare Disease Day
#Drug discovery #Rare cancers #Rare disease #Rare Disease Day

Five 2023 breakthroughs in drug discovery for rare diseases

Rare diseases are often overlooked for funding and research, but with various incentives and priority review programmes now in place, many companies are beginning to explore these unusual but often devastating conditions. This Rare Disease Day we provide an overview of the progress that has been made in… Read More

#News #Trending News

Vaccine
#AELIX Therapeutics #HIV #Immune response #Immunology / Virology & Vaccines #Phase II trial #T cell activation

HIV combination regimen could lead to viral remission

AELIX Therapeutics has announced positive results from its randomised, placebo-controlled Phase IIa therapeutic HIV vaccine and immune modulator combination clinical trial.  The AELIX-003 trial evaluated the safety, tolerability, immunogenicity and efficacy of AELIX’s HTI T-cell therapeutic HIV vaccine in combination with Gilead’s investigational Toll-Like Receptor 7 (TLR7)… Read More

#News #Trending News

T cells
#HIV #Immunocore #Phase I trial #T cell activation #T cell receptor (TCR)

Positive early data for first soluble TCR therapy for HIV

A Phase I safety and pharmacodynamic activity trial shows IMC-M113V, the first soluble T cell receptor (TCR) therapy for people living with HIV, is well tolerated.  Immunocore presented the findings at the Conference on Retroviruses and Opportunistic Infection (CROI).  The bispecific soluble TCR therapy built… Read More

#News #Trending News

Vaccine
#Covid booster #Covid-19 #Immunology / Virology & Vaccines #Phase III trial #Vaxxinity

New Covid-19 booster outperforms approved vaccines

Covid-19 booster candidate UB-612 has achieved its immunogenicity endpoints in a head-to-head trial against three vaccine platforms: mRNA (Pfizer-BioNTech’s BNT162b2), adenovirus vector (AstraZeneca’s ChAdOx1-S), and inactivated virus (Sinopharm’s BIBP).  The results show UB-612 elicits superior neutralising antibody titers and seroconversion rates against… Read More

#News #Trending News

Covid-19 vaccination
#Cardiovascular disease #Covid-19 #Covid-19 vaccine #Immunology / Virology & Vaccines

Covid-19 vaccination reduces risk of cardiac events

Researchers have revealed that vaccination against Covid-19 is associated with fewer heart attacks, strokes, and other cardiovascular issues among people who were infected with SARS-CoV-2.  The conclusions are based on analysis of the most extensive datasets in the United States by a team from the Icahn School… Read More

#News #Trending News